88 related articles for article (PubMed ID: 1981310)
21. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
22. [Gene amplification in murine leukemia cells with multiple drug resistance acquired in vivo].
Demidova NS; Goncharova SA; Chernova OB; Kopnin BP; Gudkov AV
Genetika; 1987 Oct; 23(10):1797-806. PubMed ID: 3692152
[TBL] [Abstract][Full Text] [Related]
23. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
24. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.
Haber M; Norris MD; Kavallaris M; Bell DR; Davey RA; White L; Stewart BW
Cancer Res; 1989 Oct; 49(19):5281-7. PubMed ID: 2569932
[TBL] [Abstract][Full Text] [Related]
25. Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
Volm M; Mattern J; Pommerenke EW
Anticancer Res; 1991; 11(2):579-85. PubMed ID: 1676579
[TBL] [Abstract][Full Text] [Related]
26. Scanning electron microscopy of multidrug resistant cells in haematological and mammary malignancies.
Galimberti S; Bianchi F; Bernardini N; Mattii L; Dolfi A; Lupetti M; Petrini M
Cell Mol Biol (Noisy-le-grand); 1993 Jul; 39(5):543-51. PubMed ID: 8104068
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
28. Identification of a P-glycoprotein-related protein (mini-P-glycoprotein) which is overexpressed in multidrug resistant cells.
Kawai K; Kusano I; Ido M; Sakurai M; Shiraishi T; Yatani R
Biochem Biophys Res Commun; 1994 Jan; 198(2):804-10. PubMed ID: 7905266
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
30. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
31. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
32. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
33. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
34. Novel multidrug resistance reversal agents.
Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
[TBL] [Abstract][Full Text] [Related]
35. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
36. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin).
Ganapathi R; Hercbergs A; Grabowski D; Ford J
Cancer Res; 1993 Jul; 53(14):3262-5. PubMed ID: 8100737
[TBL] [Abstract][Full Text] [Related]
37. The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity.
Kaplan O; Jaroszewski JW; Clarke R; Fairchild CR; Schoenlein P; Goldenberg S; Gottesman MM; Cohen JS
Cancer Res; 1991 Mar; 51(6):1638-44. PubMed ID: 1998955
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance of murine leukemia cells characterization and correlation with cytochrome P-450 dependent activities, cytosolic calcium and cell cycle state.
Pfeil D; Bergmann J; Fichtner I; Stein U; Hentschel M; Rothe I; Goan SR
Anticancer Res; 1994; 14(2A):571-6. PubMed ID: 7912495
[TBL] [Abstract][Full Text] [Related]
39. N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells.
Lothstein L; Wright HM; Sweatman TW; Israel M
Oncol Res; 1992; 4(8-9):341-7. PubMed ID: 1362503
[TBL] [Abstract][Full Text] [Related]
40. Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines.
Pierré A; Léonce S; Pérez V; Atassi G
Cancer Chemother Pharmacol; 1998; 42(6):454-60. PubMed ID: 9788571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
